The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal.
COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which enrolled the 1,001st photon patient on October 20, 2022.
The goal of COMPPARE is to determine quality of life among 3,000 men between the ages of 30-85 across the US who will be treated with either protons (1,500 patients) or photons (1,500 patients). Participants will answer brief surveys regarding treatment choice, quality of life, and side effects for at least 3 years.
To check study accrual progress, view enrollment updates here.